Last updated: February 19, 2026
This analysis examines key considerations for biopharmaceutical patentability, enforceability, and claim scope within the jurisdiction of the Hellenic Patent Office (HPO). It focuses on specific examination guidelines, relevant case law precedents, and strategic approaches to securing robust patent protection in Greece.
What are the Core Patentability Requirements for Biopharmaceuticals in Greece?
Biopharmaceutical inventions in Greece must meet the standard patentability criteria of novelty, inventive step, and industrial applicability. The HPO applies examination guidelines that align with the European Patent Convention (EPC), as Greece is a member of the European Patent Organisation.
Novelty
An invention is novel if it has not been made public by written or oral description, by use, or in any other way, before the filing date of the patent application [1]. For biopharmaceuticals, this means demonstrating that the specific active ingredient, formulation, or method of treatment is new. Prior art, including scientific publications, existing patents, and public disclosures, is assessed to determine if the invention has been anticipated.
Inventive Step
An invention involves an inventive step if, having regard to the state of the art, it is not obvious to a person skilled in the art [1]. For biopharmaceuticals, demonstrating an inventive step often involves showing unexpected technical effects or advantages over the prior art. This can include superior efficacy, reduced side effects, improved pharmacokinetic profiles, or novel formulations that overcome existing limitations. The "person skilled in the art" is presumed to have average knowledge and skill in the relevant biopharmaceutical field.
Industrial Applicability
An invention is capable of industrial application if it can be made or used in any kind of industry, including agriculture [1]. For biopharmaceuticals, this requirement is generally met as they are products of pharmaceutical manufacturing and can be used in medical treatment. This also extends to diagnostic methods practiced on the human or animal body, provided they are applied by a physician or veterinarian [1].
How does the HPO approach Biotechnology Inventions?
The HPO's examination of biotechnology inventions, including biopharmaceuticals, adheres to specific guidelines concerning patentable subject matter, particularly regarding human genetic material and methods of treatment.
Patentable Subject Matter
Discoveries, scientific theories, and mathematical methods are not considered inventions [1]. However, technical applications of these principles may be patentable. For biopharmaceuticals, this means that the mere discovery of a gene sequence is not patentable, but a gene sequence encoding a protein that has a specific therapeutic use, along with its isolation and modification for that use, can be.
Exclusions from Patentability
The following are explicitly excluded from patentability under Greek patent law, mirroring the EPC [1, 2]:
- Processes for cloning human beings: Any process that involves modifying the germ line genetic identity of human beings.
- Processes for modifying the germ line genetic identity of human beings: Genetic modifications that are heritable.
- Use of human embryos for industrial or commercial purposes: This includes their use for therapeutic purposes.
- Processes for modifying the genetic identity of animals which are likely to cause them suffering without any substantial medical benefit to man or animal: This balances animal welfare with potential medical advances.
- Inventions contrary to public order or morality: This is a broad category that can be invoked in exceptional cases.
Methods of Treatment
Methods for treatment of the human or animal body by surgery or therapy and diagnostic methods practiced on the human or animal body are not patentable as such [1]. This exclusion is crucial for biopharmaceutical patents. However, products, in particular substances or compositions, for use in any of these methods are patentable, provided they are new and involve an inventive step.
This means a patent cannot claim a novel drug for treating a specific disease (e.g., "A method of treating Alzheimer's disease comprising administering compound X"). Instead, the patent claim would focus on the compound itself or its use in a specific medical context.
Permissible Claim Formats for Methods of Treatment:
- First medical use claims: "Substance P for use in treating disease Y."
- Second and further medical use claims: "Substance P for use in treating disease Z, wherein disease Z is a condition distinct from previously disclosed uses of Substance P." These are crucial for extending patent protection for established drugs.
What are the Key Considerations for Claim Scope and Enforceability in Greece?
The scope of patent claims dictates the extent of protection, and enforceability ensures that those rights can be upheld against infringement. Greece's legal framework for patents is heavily influenced by EU directives and the EPC.
Claim Interpretation
Claims are interpreted in accordance with their ordinary meaning, read in the light of the description and drawings, and with due regard to the enablement and disclosure requirements [3]. The description must disclose the invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art.
Doctrine of Equivalents
While Greek patent law does not explicitly codify the "doctrine of equivalents" in the same way as some common law jurisdictions, the interpretation of claims often considers whether an alleged infringement falls within the scope of the patent based on its overall technical teaching. This means that a product or process that is not identical to what is claimed may still infringe if it performs substantially the same function in substantially the same way to achieve substantially the same result, and if a person skilled in the art would understand it to be covered by the claim. This is often analyzed through the lens of "disclosure" and "enablement."
Sufficiency of Disclosure and Enablement
A patent application must disclose the invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art [1]. For biopharmaceuticals, this is particularly critical. The disclosure must enable the skilled person to reproduce the invention without undue burden or further inventive activity. This includes providing sufficient biological data, characterization of the molecule, and manufacturing processes. Insufficient disclosure can lead to claims being deemed invalid or narrowed.
Markush Claims
In biopharmaceutical patenting, Markush claims are widely used to cover a genus of related compounds. These claims define a core structure with variable substituents, allowing for broad protection. The HPO examines Markush claims based on whether they are adequately supported by the disclosure. The disclosed embodiments must provide a reasonable basis for believing that all compounds within the scope of the Markush claim possess the claimed properties and advantages. Generalization beyond the demonstrated effects can render a Markush claim invalid for lack of support.
Experimental Data and Support
The HPO requires patent applications to be supported by sufficient experimental data to demonstrate the alleged advantages and technical effects of the invention. For biopharmaceuticals, this often includes in vitro and in vivo efficacy studies, pharmacokinetic data, and comparative studies against prior art compounds. Claims are often narrowed or rejected if they go beyond what is credibly demonstrated by the experimental evidence provided.
Supplementary Protection Certificates (SPCs)
While not directly a patentability issue, SPCs are critical for biopharmaceutical companies in Greece to recoup R&D investment lost during the regulatory approval process. An SPC extends the term of protection of a patent for a medicinal product. To obtain an SPC in Greece, the medicinal product must have been granted a marketing authorization by the relevant national or EU regulatory authorities, and the patent must be in force [4]. The duration of the SPC is calculated based on the time elapsed between the filing of the patent application and the grant of the first marketing authorization, minus five years, up to a maximum extension of five years [4].
What are the Strategic Implications for Patent Filing and Enforcement?
Navigating the Greek patent system requires a strategic approach to maximize patentability, secure broad claim scope, and facilitate effective enforcement.
Provisional Applications and Priority Claims
Greece, as an EPC member, allows for priority claims based on earlier filings (e.g., PCT applications, or filings in other EPC member states). Companies should strategically file provisional applications to establish priority dates early in the R&D process, especially for novel biopharmaceutical entities or uses.
Divisional Applications
If an application contains more than one invention, or if the HPO raises objections regarding unity of invention, divisional applications can be filed. This allows for parallel prosecution of distinct inventions or subject matter, potentially leading to multiple patents and broader overall protection.
Oppositions and Revocations
Patents granted by the HPO can be opposed within nine months of their publication. Third parties can also seek revocation of a granted patent at any time on grounds of invalidity. Companies must be prepared to defend their patents against such challenges and monitor the patent landscape for potential threats to their IP.
Infringement Analysis and Litigation
Enforcing biopharmaceutical patents in Greece typically involves litigation in the Greek civil courts. Successful enforcement requires clear and unambiguous claim language, strong supporting data, and evidence of infringement. The process can be lengthy and complex, involving expert testimony and technical analysis. Companies often seek preliminary injunctions to prevent ongoing infringement during litigation.
Freedom to Operate (FTO) Analysis
Before launching a new biopharmaceutical product in Greece, a thorough FTO analysis is essential. This involves assessing whether the proposed product or process infringes any existing valid patents held by third parties. This analysis should consider not only Greek patents but also European patents designating Greece.
Case Law Examples and Trends
While specific Greek case law on biopharmaceutical patents is less extensive than in larger jurisdictions, the HPO follows established European Patent Office (EPO) case law and decisions from the Boards of Appeal, which often serve as persuasive authority.
- Gene Patents: Following EPO guidelines, the patentability of isolated DNA sequences is generally allowed if they have a specific function and are claimed in a way that is technically applicable. The mere sequence is not patentable, but its isolation and characterization for a specific use is.
- Second Medical Use: Greek courts and the HPO recognize the patentability of second and further medical uses, similar to EPO practice. This requires a clear distinction from prior art uses and demonstration of a specific technical advantage or effect for the new use.
- Sufficiency of Disclosure for Biologics: For complex biologics, proving sufficiency of disclosure can be challenging. Applicants must provide robust characterization data and manufacturing details that enable a skilled person to produce the biologic without undue experimentation.
Key Takeaways
- Biopharmaceutical patentability in Greece hinges on novelty, inventive step, and industrial applicability, with examination aligning with EPC standards.
- Discoveries of genes or natural phenomena are not patentable; patent protection arises from their technical application.
- Methods of treatment and diagnostic methods are excluded from patentability as such, but products for use in these methods are patentable (first, second, and further medical uses).
- Claim scope is determined by literal interpretation and consideration of the overall technical teaching, with an emphasis on sufficiency of disclosure and enablement.
- Markush claims require robust experimental support to cover the claimed genus.
- Supplementary Protection Certificates (SPCs) are vital for extending effective market exclusivity beyond patent expiry.
- Strategic filing, including divisional applications and careful claim drafting, is crucial for maximizing protection.
- Enforcement requires clear claims, strong evidence, and an understanding of Greek civil litigation procedures.
FAQs
-
Can a patent be obtained for a newly discovered gene sequence in Greece?
No, a patent cannot be obtained for the mere discovery of a gene sequence. However, an isolated gene sequence that encodes a protein with a specific, identifiable function and is claimed for its industrial application (e.g., a therapeutic protein) can be patentable if it meets the criteria of novelty and inventive step.
-
What are the limitations on patenting a new formulation of an existing drug in Greece?
A new formulation of an existing drug is patentable if it demonstrates novelty and an inventive step. This typically requires showing unexpected advantages, such as improved bioavailability, stability, reduced side effects, or a novel delivery mechanism that is not obvious to a person skilled in the art.
-
How does the HPO handle patent applications claiming an invention that is already patented in another EU country?
The HPO examines patent applications independently based on Greek patent law and relevant international agreements. While other EU patents can be considered prior art, the HPO's decision is based on its own assessment of patentability criteria for Greece. A European patent granted by the EPO designating Greece is directly enforceable in Greece.
-
Is it possible to obtain broad claims for a new class of biopharmaceutical compounds in Greece?
Yes, it is possible to obtain broad claims, such as Markush claims, for a new class of compounds. However, these claims must be adequately supported by the patent application's disclosure, including sufficient experimental data demonstrating the utility and advantages of the claimed compounds to a person skilled in the art. Claims that extend beyond the demonstrated effects may be rejected or narrowed.
-
What is the typical duration of patent protection for a biopharmaceutical in Greece, considering potential extensions?
The standard term of protection for a patent in Greece is 20 years from the filing date. For medicinal products, this term can be effectively extended by up to five years through a Supplementary Protection Certificate (SPC), provided the product has obtained marketing authorization and all other conditions are met.
Citations
[1] Law No. 1733/1987 on Inventions, Utility Models and Industrial Designs, as amended.
[2] Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions.
[3] Hellenic Patent Office Examination Guidelines (unofficial compilation based on Law No. 1733/1987 and international conventions).
[4] Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products.
